January 1, 2009Thrombosis and Haemostasis
Long-term complications of medical patients with hospitalacquired venous thromboembolism
Key result
Modeling universal pharmacological thromboprophylaxis in hospitalized medical patients reduced the estimated number of long-term VTE complications over 5 years by 60% (from 180,176 to 72,337 cases).
Why the study?
Does universal pharmacological thromboprophylaxis reduce long-term complications of VTE in hospitalized medical patients?
Population
8,077,919 hospitalised medical patients at risk for VTE from the 2003 United States Healthcare Cost and…
Comparison
Universal utilisation of pharmacological… vs Current rates of pharmacological…
Design
Other
Follow-up
5 years (modeled)
Authors
Discussion
Loading...
Member takes
Implication
May support expanded prophylaxis modeling in medical inpatients; leaves open prospective trials to confirm long-term VTE benefits.
Study Design
Type
Observational (n=8,077,919)
Multicenter
Yes
Structured PICO
Does universal pharmacological thromboprophylaxis reduce long-term complications of VTE in hospitalized medical patients?
P
Population
8,077,919 hospitalised medical patients at risk for VTE from the 2003 US HCUP Nationwide Inpatient Sample database, modeled over a 5-year period.
E
Exposure
Universal utilisation of pharmacological thromboprophylaxis (modeled)
C
Comparator
Current rates of pharmacological thromboprophylaxis prescribing (ranging from 15.3% to 49.2%)
O
Outcome
Long-term complications of VTE over 5 years, including recurrent VTE, postthrombotic syndrome (PTS), chronic thromboembolic pulmonary hypertension (CTEPH), and VTE-related deathshard clinical
Main Result
Effect estimate: 60% reduction
Absolute Event Rate: 0.9% vs 2.23%
Universal pharmacological thromboprophylaxis in hospitalized medical patients could reduce long-term VTE complications, including recurrent VTE, PTS, and CTEPH, by more than half.
Cite This Study
Fanikos et al. (2009) conducted an observational in Hospital-acquired acute venous thromboembolism (VTE) (n=8,077,919). Universal pharmacological thromboprophylaxis vs. Current rates of pharmacological thromboprophylaxis prescribing (15.3% to 49.2%) was evaluated on Long-term complications of VTE (recurrent VTE, postthrombotic syndrome, and chronic thromboembolic pulmonary hypertension) (60% reduction). Modeling universal pharmacological thromboprophylaxis in hospitalized medical patients reduced the estimated number of long-term VTE complications over 5 years by 60% (from 180,176 to 72,337 cases).